Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10388MR)

This product GTTS-WQ10388MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10388MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6796MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ4590MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ6819MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ398MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ2842MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ11706MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ9137MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ5112MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW